Q-omics provides the consensus-scored WFDC13 profile across patient tissues and cancer cell-line models. WFDC13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WFDC13 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, WFDC13 RNA expression shows 11,499 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where WFDC13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WFDC13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WFDC13 survival associations across molecular data types. WFDC13 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WFDC13 RNA expression–survival associations across cancer types. High WFDC13 expression shows unfavorable associations in KIRC, LIHC, KIRP, COAD, CESC and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WFDC13 RNA expression.
This table summarizes WFDC13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for WFDC13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WFDC13 shows lower tumor expression in LUSC and higher tumor expression in KIRC, COAD, BRCA, READ and STAD. The KIRC box plot shows higher WFDC13 RNA expression in tumor versus normal tissue (log2 FC = +0.091, t-test p < 0.001).
This table shows molecular features associated with WFDC13 in patient tissues and cancer cell lines. In patient samples, WFDC13 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, WFDC13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
